Enrofloxacin is a fluoroquinolone antibiotic and a veterinary antibacterial agent. ENR is currently approve for treatment of individual pets and domestic animals in the U.S. by the U.S. Food and Drug Administration (FDA). ENR is effective against a several gram-positive and gram-negative bacteria such as pseudomonas aeroginosa, Klebsiella, and E.coli.
Asia Pacific is expected to hold dominant position in the Enrofloxacin market over the forecast period. Factors such as growing population and high demand for poultry meat are expected to impact the market growth. Moreover, significant growth in the pet industry in China is also expected to contribute to the market growth in Asia Pacific. Restrictions on the use of ENR in the U.S. is expected to adversely affect growth of the market in North America.
Key Competitors in the Enrofloxacin Industry:
1) Krka, d. d., Novo mesto
Krka, d. d., Novo mesto is an international generic pharmaceutical company. The company sells its products to more than 70 countries. Krka’s business is founded on pharmaceutical and chemical activities. Prescription pharmaceuticals remain its main product group, with an 82.6% share of Krka Group’s total sales. They are followed in sales volume by non-prescription products (9.4%) and animal health products (5%). The company was founded in the year 1954, and the headquarters are located in Novo Mesto, Slovenia.
As of April 2023, the company won the title of the most energy-efficient company in the option of the pollsters and internet users alike.
2) Chanelle Pharma
Chanelle Pharma is a leading pharmaceutical company. Chanelle Pharma provides a range of services in areas of research and product development. Chanelle Pharma holds over 4000+ human and veterinary pharmaceutical licenses in Europe, Canada, South Africa, Australia, New Zealand, and Japan. In the EU, it holds the largest number of veterinary licenses of any animal health company. The company was founded in the year 1985, and the headquarters are located in Loughrea Galway.